Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

OCS

Oculis Holding AG

13.02

Aug 10 • 4:01 AM ET +0.34 (2.68%)

Healthcare Biotechnology Switzerland Small NASD

Today, 3:05 AMOculis to buy full global rights to Privosegtor, ACT‑02 from Accure for $3.8M plus up to 2.05M shares

Peers: BMRN VKTX GKOS INCY AXSM MDGL RYTM BLCO ALC NBIX

| Held by: SBIO BBC ONEQ GWX GLCR

Scroll to Statements

Index	-
Market Cap	744.35M
Enterprise Value	470.83M
Income	-117.99M
Sales	0.00M
Book/sh	4.05
Cash/sh	4.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	60
IPO	May 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.21
P/C	2.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.18
Current Ratio	5.18
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.14
EPS next Y	-2.12
EPS next Q	-0.49
EPS this Y	16.40%
EPS next Y	-8.44%
EPS next 5Y	9.05%
EPS past 3/5Y	-26.82% -
Sales past 3/5Y	- -
EPS Y/Y TTM	19.41%
Sales Y/Y TTM	-
EPS Q/Q	18.35%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	58.87% 73.64%

Insider Own	35.22%
Insider Trans	0.00%
Inst Own	23.70%
Inst Trans	6.38%
ROA	-44.16%
ROE	-55.07%
ROIC	-47.77%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.41%
SMA50	5.19%
SMA200	-40.09%
Trades

Shs Outstand	60.39M
Shs Float	37.03M
Short Float	4.06%
Short Ratio	2.19
Short Interest	1.51M
52W High	34.47 -62.23%
52W Low	10.52 23.76%
Volatility	5.10% 5.34%
ATR (14)	0.73
RSI (14)	55.65
Beta	0.25
Rel Volume	0.04
Avg Volume	687.12K
Volume	1,535

Perf Week	9.50%
Perf Month	-4.48%
Perf Quarter	-60.11%
Perf Half Y	-54.28%
Perf YTD	-34.80%
Perf Year	-28.50%
Perf 3Y	1.88%
Perf 5Y	34.92%
Perf 10Y	-
Recom	1.09
Target Price	36.26
Prev Close	12.68
Price	13.02
Change %	2.68%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-26	Initiated	Guggenheim	Buy	$75
Dec-19-25	Initiated	JP Morgan	Overweight	$38
Aug-27-25	Initiated	Needham	Buy	$36
Dec-05-23	Initiated	Chardan Capital Markets	Buy	$30
Oct-05-23	Initiated	Stifel	Buy	$35
Jun-14-23	Initiated	BofA Securities	Buy	$22
Jun-12-23	Initiated	H.C. Wainwright	Buy	$28
Jun-08-23	Initiated	Robert W. Baird	Outperform	$58
May-10-23	Initiated	Pareto	Buy	$23
Apr-28-23	Initiated	Wedbush	Outperform	$27

Today 03:30AM	Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company (GlobeNewswire)
Aug-06-26 04:05PM	Oculis Reports Q2 2026 Financial Results and Provides Company Update (GlobeNewswire)
Aug-05-26 09:33AM	Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result (GuruFocus.com)
Aug-03-26 04:00AM	Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses (GlobeNewswire) +5.13%
Jul-08-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
04:00AM	Loading…
Jul-02-26 04:00AM	Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference (GlobeNewswire)
Jun-15-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jun-11-26 04:00AM	Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 (GlobeNewswire)
Jun-10-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jun-09-26 03:21PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
04:00AM	Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease (GlobeNewswire)
Jun-08-26 03:25PM	Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-29-26 04:18PM	OCS Stock Drops Over 23% Eye Drop Trial For Diabetic Vision Loss Misses Target (Stocktwits) -23.42% -36.09%
04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
03:06PM	Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema (GlobeNewswire)
04:05PM	Loading…
May-28-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
May-21-26 09:40AM	Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls (The Fly) +11.07%
May-15-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) -7.33%
May-14-26 04:05PM	Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors (GlobeNewswire)
May-11-26 04:07PM	Oculis Reports Q1 2026 Financial Results and Provides Company Update (GlobeNewswire) -6.86%
May-07-26 05:00AM	Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial (GlobeNewswire) +5.10%
May-06-26 09:25AM	Oculis Holding AG (OCS) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +6.59%
May-05-26 04:00AM	Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting (GlobeNewswire)
May-01-26 04:00AM	Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Apr-21-26 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire)
Apr-20-26 04:00AM	Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Apr-08-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Apr-07-26 04:00AM	Oculis to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-31-26 05:00AM	Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis (GlobeNewswire) +8.31%
Mar-27-26 05:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
05:00AM	Loading…
Mar-16-26 05:00AM	Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting (GlobeNewswire)
03:24AM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-13-26 05:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) -6.15%
Mar-11-26 05:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-06-26 04:01PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-05-26 04:00AM	Oculis to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:00AM	Oculis Publishes 2025 Consolidated Financial Statements (GlobeNewswire)
Mar-04-26 04:15PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-03-26 05:35PM	Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update (GlobeNewswire)
Mar-02-26 07:17AM	Earnings To Watch: Oculis Holding AG (OCS) Reports Q4 2025 Result (GuruFocus.com)
Feb-27-26 04:15PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Feb-18-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated (GlobeNewswire)
Feb-17-26 04:00AM	Oculis Appoints Katie Kazem as Chief Legal Officer (GlobeNewswire)
Jan-09-26 06:04AM	J.P. Morgan Bangs the Drum on These 2 Strong Buy Stocks (TipRanks)
Jan-08-26 04:00AM	Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference (GlobeNewswire) +5.05%
Jan-06-26 04:34PM	S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge (Barchart) +5.82%
04:00AM	Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis (GlobeNewswire)
Jan-05-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Dec-09-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Dec-08-25 09:55AM	Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know (Zacks) -5.03%
Dec-03-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
12:00PM	Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-28-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Nov-18-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Nov-10-25 05:15PM	Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q3 2025 Financial Results and Provides Company Update (GlobeNewswire)
Nov-06-25 09:10AM	Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates (Zacks)
Nov-05-25 07:41AM	Oculis Holding AG (OCS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
04:00AM	Oculis to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-30-25 04:30AM	Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development (GlobeNewswire) -6.77%
Oct-24-25 04:38AM	Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Oct-14-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
04:00AM	Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 (GlobeNewswire)
Oct-10-25 08:54AM	Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-08-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) +6.34%
Oct-06-25 04:07AM	Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy (GlobeNewswire) +5.61%
Sep-26-25 04:05PM	Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities (GlobeNewswire)
Sep-23-25 10:24AM	Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? (Zacks)
Sep-22-25 04:00AM	Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS (GlobeNewswire) +6.68%
Sep-09-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Sep-04-25 01:00PM	Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 (GlobeNewswire)
Sep-03-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Sep-01-25 04:00AM	Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences (GlobeNewswire)
Aug-28-25 04:00AM	Oculis to Participate in Upcoming September Investor Conferences (GlobeNewswire) -5.63%
Aug-25-25 04:00AM	Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors (GlobeNewswire)
Aug-21-25 05:15PM	Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q2 2025 Financial Results and Provides Company Update (GlobeNewswire)
Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-13-25 09:25AM	Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-12-25 05:30PM	Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00AM	Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-07-25 05:25PM	CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 (Zacks)
Aug-06-25 09:50AM	YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? (Zacks)
08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks)
Aug-01-25 04:00AM	Oculis Upsized Loan Facility to Access up to CHF 100 million (GlobeNewswire)
Jul-09-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jun-09-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jun-05-25 04:00AM	Oculis Publishes Results of 2025 Annual General Meeting (GlobeNewswire)
Jun-03-25 05:00PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
04:00AM	Oculis to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-09-25 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire) -5.27%
May-08-25 06:10PM	Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q1 Financial Results and Provides Company Update (GlobeNewswire)
10:00AM	BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-07-25 10:00AM	Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline (Zacks)
04:00AM	Oculis to Present at Upcoming May Investor Conferences (GlobeNewswire)
May-01-25 04:00AM	Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences (GlobeNewswire)
Apr-25-25 04:00PM	Oculis Updates Share Capital (GlobeNewswire) -5.82% +5.06%
Apr-17-25 05:00AM	Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award (GlobeNewswire)

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

M.D.Dr. Riad Sherif M.B.A.

Chief Financial OfficerMs. Sylvia Cheung

Chief Technology OfficerMs. Gudrun Bachmann Ph.D.

Ph.D.Dr. Ramin Tadayoni M.D.

Chief Legal OfficerMs. Katie Kazem

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Sherif Riad	Officer	Mar 09 '26	Proposed Sale	26.40	25,000	660,000	Mar 09 04:08 PM
CHRISTINA ACKERMANN	Director	Oct 09 '25	Proposed Sale	19.87	7,460	148,230	Oct 09 04:22 PM
Sherif Riad	Officer	Sep 23 '25	Proposed Sale	17.70	25,000	442,500	Sep 23 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCS

Oculis Holding AG

Upgrade your Finviz experience